ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Formulation and Box-Behnken optimization of roflumilast loaded ultradeformable nanotransethosomal gel: physicochemical characterization, stability, dermal permeation, and antipsoriatic efficacy in an imiquimod-induced psoriasis model.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to formulate and optimise a roflumilast loaded ultradeformable transethosomal gel for enhanced topical delivery in psoriasis management, addressing limitations of conventional topical preparations through an advanced vesicular drug delivery approach. Ultradeformable transethosomes were prepared by the ethanol injection technique and optimised using a Box-Behnken experimental design. Independent variables selected were Phospholipon 90G (400-500 mg), Poloxamer 188 (1-3% w/v), and ethanol (20-40% v/v). Dependent responses were vesicle size (Y
Indexed as
Identifiers
42733014What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.